We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Cases · May 25, 2021

Next Steps for Recurrent HR+ Ductal Carcinoma

Written by
Ana C. Sandoval Leon MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Jose A Garcia-Saenz

    May 28, 2021

    Retest immunochemistry study in the liver biopsy, first.

  • Carlos Calderon

    May 28, 2021

    After reviewing the immunohistochemistry, if local luminal b and triple negative metastasis are confirmed then surgical control of local recurrence, followed by radiotherapy and bilateral oophorectomy. Start capecitabine. A genetic panel would be important.

  • iveta andrezalova

    Jun 02, 2021


  • oscar aballay

    Jun 03, 2021


  • Jan 27, 2022

    Pending Moderator approval.

Further Reading